ConvaTec Group PLC (LON:CTEC – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is GBX 308.78.
CTEC has been the topic of several research analyst reports. UBS Group reiterated a “buy” rating and issued a GBX 375 price objective on shares of ConvaTec Group in a report on Monday, May 18th. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 325 price objective on shares of ConvaTec Group in a report on Friday, May 15th. Citigroup cut their price objective on ConvaTec Group from GBX 250 to GBX 230 and set a “neutral” rating on the stock in a report on Monday, May 18th. Stifel Nicolaus reiterated a “buy” rating and issued a GBX 315 price objective on shares of ConvaTec Group in a report on Wednesday, March 11th. Finally, JPMorgan Chase & Co. cut their price objective on ConvaTec Group from GBX 307 to GBX 294 and set an “overweight” rating on the stock in a report on Friday, May 22nd.
View Our Latest Report on CTEC
Insider Activity
ConvaTec Group Price Performance
CTEC stock opened at GBX 202.85 on Tuesday. The company has a current ratio of 1.53, a quick ratio of 0.96 and a debt-to-equity ratio of 106.19. The company has a market capitalization of £3.96 billion, a PE ratio of 23.59, a P/E/G ratio of 0.93 and a beta of 0.78. ConvaTec Group has a 12-month low of GBX 195.50 and a 12-month high of GBX 311.20. The business’s fifty day moving average price is GBX 217.15 and its 200 day moving average price is GBX 229.28.
ConvaTec Group Company Profile
ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.
See Also
- Five stocks we like better than ConvaTec Group
- Costco’s Strong Quarter Still Leaves Investors With a Valuation Problem
- These 3 Software Stocks Are Buying Back Shares Hand Over Fist
- Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17%
- MongoDB’s AI Advantage Is Starting to Show Up in Results
Receive News & Ratings for ConvaTec Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConvaTec Group and related companies with MarketBeat.com's FREE daily email newsletter.
